Investment Banking

Lazard CEO Jacobs sees ‘pent up’ M&A demand after record 83% profit surge

Ken Jacobs told Financial News that increased confidence following the rollout of the Covid-19 vaccine, as well as expansionary technology-enabled companies was fuelling more dealmaking

Lazard advised on healthcare firm Gilead’s $21bn acquisition of cancer drug-maker Immunomedics
Lazard advised on healthcare firm Gilead’s $21bn acquisition of cancer drug-maker Immunomedics Photo: Getty Images

Lazard chief executive, Ken Jacobs, sees "pent up demand" for M&A fuelling results in 2021 after the independent investment bank ended the year with its a record quarter for its advisory business.

Jacobs told Financial News that increased confidence following the rollout of the Covid-19 vaccine, as well as expansionary technology-enabled companies was fuelling more dealmaking.

WSJ Logo
Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With TrumpExternal link

Pro Bono or Pro Nono? Law Firms Split on Fulfilling Deals With Trump